iOnctura Raises EUR 80 Million to Propel Groundbreaking Cancer Treatments
iOnctura, a pioneering biopharmaceutical company specializing in innovative cancer treatments, has secured EUR 80 million in Series B financing. This milestone funding round, led by Syncona Limited with participation from the European Innovation Council (EIC) Fund and existing investors, underscores iOnctura’s transformative strides in oncology. The investment will accelerate the development of iOnctura’s lead candidate,…